237 related articles for article (PubMed ID: 22521015)
1. [Clinical effectiveness and economical evaluation of preventive vaccination].
Vaz Carneiro A; Belo AI; Gouveia M; Costa J; Borges M
Acta Med Port; 2011; 24(4):565-86. PubMed ID: 22521015
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
3. [Vaccination--value for money?].
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
[TBL] [Abstract][Full Text] [Related]
4. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
[TBL] [Abstract][Full Text] [Related]
5. Prevention of pneumococcal disease through vaccination.
Gentile A; Bazán V
Vaccine; 2011 Sep; 29 Suppl 3():C15-25. PubMed ID: 21896348
[TBL] [Abstract][Full Text] [Related]
6. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.
Pickering LK; Baker CJ; Freed GL; Gall SA; Grogg SE; Poland GA; Rodewald LE; Schaffner W; Stinchfield P; Tan L; Zimmerman RK; Orenstein WA;
Clin Infect Dis; 2009 Sep; 49(6):817-40. PubMed ID: 19659433
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
8. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
[TBL] [Abstract][Full Text] [Related]
10. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
11. [The contribution of social medicine to vaccination in Austria].
Kunze M
Wien Med Wochenschr; 1998; 148(8-9):191-7. PubMed ID: 9677675
[TBL] [Abstract][Full Text] [Related]
12. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
Sante; 2003; 13(4):215-23. PubMed ID: 15047438
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
14. Vaccines against influenza A (H1N1) pandemic.
Valdespino-Gomez JL; Garcia-Garcia L; de León-Rosales SP
Arch Med Res; 2009 Nov; 40(8):693-704. PubMed ID: 20304259
[TBL] [Abstract][Full Text] [Related]
15. Expanding the recommendations for annual influenza vaccination to school-age children in the United States.
Fiore AE; Epperson S; Perrotta D; Bernstein H; Neuzil K
Pediatrics; 2012 Mar; 129 Suppl 2():S54-62. PubMed ID: 22383482
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
17. The ins and outs of universal childhood influenza vaccination.
Fraaij PL; Bodewes R; Osterhaus AD; Rimmelzwaan GF
Future Microbiol; 2011 Oct; 6(10):1171-84. PubMed ID: 22004036
[TBL] [Abstract][Full Text] [Related]
18. Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.
McIntyre P; Amin J; Gidding H; Hull B; Torvaldsen S; Tucker A; Turnbull F; Burgess M
Commun Dis Intell; 2000 Jun; Suppl():v-83. PubMed ID: 12049363
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of influenza vaccination of healthy children.
Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
[TBL] [Abstract][Full Text] [Related]
20. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
